Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients.
about
Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular DiseaseFrom bones to blood pressure, developing novel biologic approaches targeting the osteoprotegein pathway for pulmonary vascular diseaseBone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients.Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.Fetuin-mineral complex reflects extraosseous calcification stress in CKDLong Term Effect of High Glucose and Phosphate Levels on the OPG/RANK/RANKL/TRAIL System in the Progression of Vascular Calcification in rat Aortic Smooth Muscle CellsOsteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria.An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunctionOsteoprotegerin in Cardiometabolic Disorders.Secretion patterns of circulating osteoprotegerin and response to acute and chronic energy deprivation in young healthy adults.Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension.Osteoprotegerin as a marker of atherosclerosis in diabetic patients.The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.Association between osteoprotegerin gene polymorphisms and cardiovascular disease in type 2 diabetic patientsThe role of osteoprotegerin in cardiovascular disease.Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications.Evolution of silent myocardial ischaemia prevalence and cardiovascular disease risk factor management in Type 2 diabetes over a 10-year period: an observational study.Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men.SNP rs2073618 of the osteoprotegerin gene is associated with diabetic retinopathy in Slovenian patients with type 2 diabetes.Letter to the Editor Regarding: Diabetic Peripheral Neuropathy as a Predictor of Asymptomatic Myocardial Ischemia in Type 2 Diabetes Mellitus: A Cross-Sectional StudyOsteoprotegerin, leptin and IL-6: association with silent myocardial ischemia in type 2 diabetes mellitus.Effects of pravastatin on serum osteoprotegerin levels in patients with hypercholesterolemia and type 2 diabetes.The role of serum osteoprotegerin and S-100 protein levels in patients with acute ischaemic stroke: determination of stroke subtype, severity and mortality.Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes.The Role of Osteoprotegerin as a Cardioprotective Versus Reactive Inflammatory Marker: the Chicken or the Egg Paradox
P2860
Q26747224-C71680DD-1760-4581-9741-46FB9D09ECEBQ28076305-6E5E3FC7-F41C-4D49-BDC3-795D4E7DFBBDQ34261737-53E806D8-DADC-4C16-A63E-4E13520879CBQ34399438-83692953-6A3F-41AE-8584-117201EB1FB3Q34457107-62F31BCF-48F3-4396-A22D-0327B36C8123Q35127451-20F34FA3-1502-41FE-B1E1-DC228F23B947Q35183117-26560B8F-D546-42CA-A79B-F574B75AC1DAQ35569854-0C8B0693-D954-43F3-8FDB-D1A721ADD985Q35640787-BFEA09AB-CDC3-4597-8BA3-EF0E2EEBEBEFQ36134703-3437790D-1A30-411D-BDBE-C01711FEF63FQ36357434-A96B36B3-B492-4477-8710-BAC41AF3FBA5Q36582644-3D52EECB-75A0-4D7F-98DA-D96252AA7091Q36686037-C1509AD7-E185-4604-A022-8D4DE8B87AA1Q37024429-47C64DC7-895A-45D0-97EB-8F52EAAC9F23Q38056541-0B335CB9-4D78-4B86-B172-3AA7B0DFBDC4Q38411782-E42CD9EF-33BD-4C8E-8C18-95717ACA2D8CQ40238177-95E88C72-CBDB-4ACD-8F53-BB3C5F81DF76Q42013167-32F55DD8-409D-49BE-9CE2-4F883DCE006FQ42181735-8DED897F-8DC2-43DE-AC1A-E560AA467552Q42385968-E7DABB7F-C1F9-49C6-A064-DDF8D9E0B6F4Q44967650-DDCF0E2D-4025-4C30-9EC3-45BB5A850FB1Q46160839-093A1A06-5362-49A9-9405-EE3B2A4FB78BQ48961249-C796D28F-E175-4C98-BBC1-0C0D9C0616C3Q51375055-075C1499-4FCC-4010-97B5-CF11C1A47445Q55285084-DFA98012-8E53-40A7-A855-531967009D1A
P2860
Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Osteoprotegerin is associated ...... atic type 2 diabetic patients.
@en
Osteoprotegerin is associated ...... atic type 2 diabetic patients.
@nl
type
label
Osteoprotegerin is associated ...... atic type 2 diabetic patients.
@en
Osteoprotegerin is associated ...... atic type 2 diabetic patients.
@nl
prefLabel
Osteoprotegerin is associated ...... atic type 2 diabetic patients.
@en
Osteoprotegerin is associated ...... atic type 2 diabetic patients.
@nl
P2093
P1433
P1476
Osteoprotegerin is associated ...... matic type 2 diabetic patients
@en
P2093
Antoine Avignon
Ariane Sultan
Jean Paul Cristol
Stéphane Elaerts
P304
P356
10.2337/DIACARE.28.9.2176
P407
P577
2005-09-01T00:00:00Z